Medicare Enrolled

Dr. Mohammad Kamal, M.D.

Medical Oncology · Ocala, FL
Low-engagement
4945 SW 49TH PL, Ocala, FL 34474
3522379430
In practice since 2007 (18 years)
NPI: 1699975755 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kamal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kamal? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kamal

Dr. Mohammad Kamal is a medical oncology in Ocala, FL, with 18 years in practice.

Between the years covered by Open Payments, Dr. Kamal received a total of $8,578 from 68 pharmaceutical and/or device companies across 479 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kamal is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice$ $8,578 industry payments

Industry Payment Transparency

Open Payments through 2023 ↗
$8,578
Total received (2018-2023)
Avg $1,430/year across 6 years
Top 47% in FL for medical oncology
68
Companies
479
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,405 (98.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$173 (2.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2023
$31
2022
$1,483
2021
$2,391
2020
$1,865
2019
$1,662
2018
$1,146

Payments by company (2023)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$778
Novartis Pharmaceuticals Corporation
$639
Celgene Corporation
$610
Daiichi Sankyo Inc.
$580
E.R. Squibb & Sons, L.L.C.
$497
PFIZER INC.
$444
AstraZeneca Pharmaceuticals LP
$378
Amgen Inc.
$344
Lilly USA, LLC
$274
Merck Sharp & Dohme Corporation
$258
Seagen Inc.
$253
GE HEALTHCARE
$195
Takeda Pharmaceuticals U.S.A., Inc.
$185
GENZYME CORPORATION
$183
Foundation Medicine, Inc.
$181
Eisai Inc.
$178
Bayer HealthCare Pharmaceuticals Inc.
$172
Astellas Pharma US Inc
$171
GlaxoSmithKline, LLC.
$168
Genentech USA, Inc.
$168
Heron Therapeutics, Inc.
$134
Incyte Corporation
$102
AngioDynamics, Inc.
$94
Kite Pharma, Inc.
$94
Boehringer Ingelheim Pharmaceuticals, Inc.
$86
Merck Sharp & Dohme LLC
$81
Clovis Oncology, Inc.
$68
Regeneron Healthcare Solutions, Inc.
$63
ARRAY BIOPHARMA INC
$63
Ipsen Biopharmaceuticals, Inc
$57
Seattle Genetics, Inc.
$56
Gilead Sciences, Inc.
$54
Jazz Pharmaceuticals Inc.
$51
PUMA BIOTECHNOLOGY, INC.
$51
EISAI INC.
$50
TerSera Therapeutics LLC
$48
Puma Biotechnology, Inc.
$47
AMAG Pharmaceuticals, Inc.
$46
Dova Pharmaceuticals
$45
Agios Pharmaceuticals, Inc.
$45
Rigel Pharmaceuticals, Inc.
$43
Aurobindo Pharma USA, Inc.
$42
Dendreon Pharmaceuticals LLC
$41
Teva Pharmaceuticals USA, Inc.
$36
Karyopharm Therapeutics Inc.
$35
Taiho Oncology, Inc.
$33
TESARO, Inc.
$28
Global Blood Therapeutics, Inc.
$26
AbbVie Inc.
$24
SERVIER PHARMACEUTICALS LLC
$23
Aveo Pharmaceuticals, Inc.
$20
JAZZ PHARMACEUTICALS INC.
$18
Lexicon Pharmaceuticals, Inc.
$18
Advanced Accelerator Applications
$17
Janssen Pharmaceuticals, Inc
$16
Myriad Genetic Laboratories, Inc.
$15
Pharmacyclics LLC, An AbbVie Company
$14
BeiGene USA, Inc.
$14
EMD Serono, Inc.
$14
Partner Therapeutics, Inc.
$13
SANOFI-AVENTIS U.S. LLC
$13
Kyowa Kirin, Inc.
$13
Epizyme, Inc.,
$13
MEDIVATION FIELD SOLUTIONS LLC
$12
MorphoSys, US Inc.
$12
EUSA Pharma (US) LLC
$12
Blue Earth Diagnostics Limited
$11
Alexion Pharmaceuticals, Inc.
$11
Top 3 companies account for 23.6% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALIMTA · Aliqopa · Axumin · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CALQUENCE · CEREZYME · CINVANTI · COSELA · CREON · CYRAMZA · Cinvanti · DARZALEX · Doptelet · ELITEK · ENHERTU · ERLEADA · Enhertu · Erleada · FERAHEME · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Inrebic · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MEKINIST · MONJUVI · NANOKNIFE · NERLYNX · NINLARO · Neulasta · Nplate · Nubeqa · ONUREG · OPDIVO · OXBRYTA · PADCEV · PIQRAY · POTELIGEO · PROMACTA · PROVENGE · Perjeta · Pomalyst · Prolia · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rubraca · SARCLISA · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · Somatuline Depot · Stivarga · Sustol · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Trodelvy · Ultomiris · VELCADE · VENCLEXTA · VERZENIO · Vitrakvi · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · ZEJULA · ZEPZELCA · ZOLADEX · Zevalin · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a medical oncology in Ocala?
Compare medical oncologys in the Ocala area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
6
Per 100K population
1.5
County median income
$58,535
Nearest hospital
ADVENTHEALTH OCALA
0.0 mi

Data Sources

Provider Registry✓ NPPESWeekly updates
Medicare Enrollment✓ PECOSMonthly updates
Practice Data— No dataN/A
Industry Payments✓ Open PaymentsCY 2023
Disciplinary History— Not publicN/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Kamal is a medical oncology, and low-engagement industry engagement, with 18 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Kamal receive payments from pharmaceutical companies?
Yes. Dr. Kamal received a total of $8,578 from 68 companies across 479 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Kamal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Medical Oncologys in Ocala
Browse medical oncologys in Ocala ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →